Get the Stockscreener App
3.98
36.77%
1.07
Clearmind Medicine Inc stock is traded at $3.98, with a volume of 41.74M.
It is up +36.77% in the last 24 hours and down -34.81% over the past month.
Clearmind Medicine Inc is a clinical-stage pharmaceutical company engaged in Phase I/IIa clinical trials of novel psychedelic medicines. The Company focuses on developing treatments for mental health disorders, including alcohol use disorder (AUD), binge drinking, and eating disorders. Its activities are centered on the research and development of 5-methoxy-2-aminoindane (MEAI). It operates through a single research and development segment, which is conducted in Israel.
See More
Previous Close:
$2.91
Open:
$3.71
24h Volume:
41.74M
Relative Volume:
21.97
Market Cap:
$4.06M
Revenue:
-
Net Income/Loss:
$-6.64M
P/E Ratio:
-0.2203
EPS:
-18.0702
Net Cash Flow:
$-5.60M
1W Performance:
+11.17%
1M Performance:
-34.81%
6M Performance:
-92.29%
1Y Performance:
-98.94%
1-Day Range:
$3.26
$4.5499
1-Week Range:
$2.5901
$4.5499
52-Week Range:
$2.10
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
3.98 | 2.97M | 0 | -6.64M | -5.60M | -18.07 |
VRTX
Vertex Pharmaceuticals Inc
|
446.83 | 112.12B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
635.45 | 65.92B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
891.32 | 52.38B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.05 | 40.54B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 33.10B | 742.00K | -1.37B | -1.07B | -7.0731 |
Clearmind Medicine Inc Stock (CMND) Latest News
Clearmind Medicine jumps 24.1% as traders react to fresh CMND-100 updates and upcoming June 10 webinar - Quiver Quantitative
CMND Stock Jumps As Clearmind Wins Key Trial, IP Milestones - StocksToTrade
CMND Stock Jumps As Clearmind Advances Trials And Expands IP - timothysykes.com
$Clearmind Medicine (CMND.US)$ - Moomoo
Clearmind Medicine to Present CMND-100 Clinical Trial Data on June 5, 2026 - geneonline.com
Clearmind Medicine Inc. to Host Live Webinar on MEAI and Alcohol Use Disorder with Yale and Johns Hopkins on June 10, 2026 - Quiver Quantitative
Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar - marketscreener.com
Clearmind Medicine Shares On The Move With Cash Question Looming - Bez Kabli
CMND News | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Why Did CMND Stock Jump 40% Today? - Stocktwits
CMND Technical Analysis | Trend, Signals & Chart Patterns | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Clearmind Medicine Company Profile & Introduction - Moomoo
CMND Stock Price, Quote & Chart | CLEARMIND MEDICINE INC (NASDAQ:CMND) - ChartMill
Clearmind Medicine (CMND) Revenue BreakdownMain Composition - Moomoo
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
CMND Stock Quote Price and Forecast - CNN
Clearmind announces Japanese patent application for MEAI depression treatment By Investing.com - Investing.com South Africa
Clearmind announces Japanese patent application for MEAI depression treatment - Investing.com UK
CMND Stock Jumps As Clearmind Advances Trials And IP Push - StocksToTrade
CMND Stock Spikes As Clearmind Advances Johns Hopkins Trial - timothysykes.com
Clearmind Medicine stock surges 95% on Japan patent filing By Investing.com - Investing.com Canada
Clearmind Medicine stock surges 95% on Japan patent filing - Investing.com
Clearmind Medicine Inc. Announces Publication of Japanese Patent Application for MEAI in Depression Treatment - Quiver Quantitative
Clearmind Medicine Advances Global Intellectual Property Portfolio with Japanese Patent Filing for Innovative Psychedelic- Based Depression Treatment - The Manila Times
Clearmind Medicine(CMND) Stock Options Chain | Quotes & News - Moomoo
Clearmind receives Johns Hopkins IRB approval for trial parts - Investing.com UK
Clearmind Medicine Advances Cmnd-100 Phase I/Ii Clinical Trial to Next Parts - marketscreener.com
Clearmind receives Johns Hopkins IRB approval for trial parts By Investing.com - Investing.com Australia
Clearmind Medicine stock gains on Johns Hopkins trial approval By Investing.com - Investing.com Nigeria
Clearmind Medicine stock gains on Johns Hopkins trial approval - Investing.com
Clearmind Medicine Announces Johns Hopkins IRB Approval to Advance CMND-100 Phase I/II Clinical Trial to the Next Parts - The Manila Times
Clearmind Medicine (Nasdaq: CMND) wins IRB nod to advance CMND-100 trial - Stock Titan
Clearmind Medicine Inc. Receives IRB Approval for Phase I/II Clinical Trial of CMND-100 in Alcohol Use Disorder - Quiver Quantitative
Cash from financing activities of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Net income before discontinued operations of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Total liabilities & shareholders' equities of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Clearmind Medicine Inc. Balance Sheet – LS:A427B1 - TradingView
Price to earnings ratio of Clearmind Medicine Inc. – LS:A427B1 - TradingView
Clearmind Medicine Inc. Dividends – LS:A427B1 - TradingView
Clearmind Medicine Inc. Earnings and Revenue – LS:A427B1 - TradingView
Is Clearmind Medicine (NASDAQ:CMND) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Clearmind Medicine to implement 1-for-10 reverse share split - MSN
Clearmind Medicine stock tumbles on reverse share split plan By Investing.com - Investing.com Nigeria
Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings - Benzinga
Clearmind Medicine Inc Stock (CMND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.13%
3.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):